Puretech founded entity akili announces positive results from shionogi's phase 3 clinical trial of localized version of akili's endeavorrx ® for pediatric adhd patients in japan

Boston--(business wire)--puretech health plc (nasdaq: prtc, lse: prtc) ("puretech" or the "company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its founded entity akili, inc. (nasdaq: akli) announced that its japanese partner shionogi & co. ltd has submitted akili's digital therapeutic sdt-001 for marketing approval with the ministry of health, labor, and welfare. sdt-001 is the japanese, localized version of a.
AKLI Ratings Summary
AKLI Quant Ranking